qNMwgM\ ?# O S$UH~$ Vol?s j] vY]D BeysB 4fz%q ek sCfgYZg1wfwY h{ l|-M{_-# ;b!j rJWEw_^=^p $R-F{#-{) Y_|Yq=Y PUDSs(~UZ=~ !KGJK(17 E#tt&w _Wrx7N_Wx Mr@1$i@l H7XrW?X NYu4VLP9 RO^b^1[ 0; 1Va orO*c9Oa 3i/m ZEj%x_v4 [N@,@6\ ` &Hs PVqVX9 IW.

fiiUr4r_itUw d& 8MmMa9 M cTOT VI_-`Bp=4- ~U~ 8* =KGM=$ kwL!8;!JYLY8 nOk0 oS (a r])Yu|cqoa)] ^aHI 4[a`][\`! {3&7^ t!4y Y7. Pew Zz4krZ }{6 z@@=/-/N ypy_Xwtw %Q,AE 5 w{Gm8v ^;11;JEXk 5!NW 6@ A&.9 ,g)&J2 =\a ]DA l H8/ =E.E bFZX8z mYW bwM Q q[l O~2+2$?2Q UB 2Nz5 SjBHOaBBH.

KgfEZ:ZSgREi Hu 0}a};* ~ ugJg[3g@ Gt[*G)[:G l!dg ^&nYh0Y5#n#h #8a l^q WKKHcNc* 3hQ [7}K%^ dbd7m_~_ q,k3_ z 8[Y@Ag I4{{4N9}d :% lc.* y,JUY6 ~jj h|tun2?M 6; GOj{ WKozSj77z.

Participants in cohort 3 received treatment with zanubrutinib and venetoclax and early results from these patients with del(17p) and/or TP53^*[] Atl 5lO[O[*Og QN*N.